E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10018250 |
E.1.2 | Term | Giant cell arteritis |
E.1.2 | System Organ Class | 10047065 - Vascular disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of guselkumab compared to placebo, in combination with a 26-week glucocorticoid (GC) taper regimen, in adult participants with new-onset or relapsing giant cell arteritis (GCA) |
|
E.2.2 | Secondary objectives of the trial |
- To evaluate the efficacy of guselkumab compared to placebo, in combination with a 26-week GC taper regimen, in adult participants with new-onset or relapsing GCA as measured by alternative definitions of GC free remission, GC-sparing effects, and prevention of disease flares. - To evaluate the safety of guselkumab, in combination with a 26-week GC taper regimen, in adult participants with new-onset or relapsing GCA. - To evaluate the PK and immunogenicity of guselkumab, in combination with a 26-week GC taper regimen, in adult participants with new-onset or relapsing GCA.
Exploratory Objectives for the Long-Term Extension (LTE) period - To evaluate long-term efficacy of guselkumab in adult participants with new-onset or relapsing GCA - To evaluate the continued safety of guselkumab in adult participants with new-onset or relapsing GCA. - To evaluate the PK and immunogenicity of guselkumab, in adult participants with new-onset or relapsing GCA.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female 2. At least 50 years of age, inclusive 3. Diagnosis of GCA according to the revised American College of Rheumatology criteria 4. Temporal artery biopsy revealing features of GCA either at time of diagnosis or at other timepoint during disease history OR, Evidence of cranial GCA either at time of diagnosis or at other timepoint during disease history by doppler-ultrasound, cranial Magnetic Resonance Imaging or Magnetic Resonance Angiography, or other imaging modality upon agreement with the sponsor. 5. Have new onset or relapsing GCA 6. Have active GCA within 6 weeks of first study intervention
Inclusion criterion for LTE period 1. Has completed Week 52 visit of the main study, AND has no signs and symptoms of active GCA, AND completed treatment study intervention according to the protocol, AND completed 26-week protocol defined GC-taper without the need to use rescue medication for GCA, AND has not experienced a GCA flare through Week 52. 2. Has not had any study intervention-related SAE or severe AE 3. Is able and willing to continue (blinded) treatment with study intervention
Please see section 5.1 in the protocol for all inclusion criteria. |
|
E.4 | Principal exclusion criteria |
1. Has any known severe or uncontrolled GCA complications 2. Has any rheumatic disease other than GCA such as Takayasu's Arteritis, granulomatosis with polyangiitis (Wegener's), RA, systemic lupus erythematosus that could interfere with assessment of GCA 3. Has a current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances 4. Has or has had any major ischemic event, within 12 weeks of first study intervention 5. Has a history of lymphoproliferative disease, including lymphoma; a history of monoclonal gammopathy of indetermined significance; or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy or splenomegaly 23. Has started Methotrexate (MTX) within 12 weeks of first study intervention. If started MTX >12 weeks prior to first study intervention MTX must have been at a stable dose for minimally 4 weeks and must not be receiving more than 25 mg oral or SC MTX per week
Please see section 5.2 in the protocol for all exclusion criteria. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The proportion of participants achieving GC-free remission |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- The proportion of participants achieving GC-free remission from Week 28 by visit through Week 52 - The proportion of participants achieving GC-free remission and normalization of erythrocyte sedimentation rate (ESR) at Week 28 and by visit through Week 52 - The proportion of participants achieving GC-free remission and normalization of C-reactive protein (CRP) at Week 28 and by visit through Week 52 - The proportion of participants achieving GC-free remission and normalization of both ESR and CRP at Week 28 and by visit through Week 52 - The cumulative GC dose through Week 28 and through Week 52 - The time to first GCA disease flare or discontinuation of study intervention due to AE of worsening of GCA through Week 28 and through Week 52 - The number of GCA disease flares or discontinuation of study intervention due to AE of worsening of GCA through Week 28 and through Week 52
Endpoints for the Long-Term Extension (LTE) period - Assessment of IL-23 pathway related and disease related biomarkers in serum and whole blood at Week 104 (LTE Week 52) Large-Vessel Imaging (FDG-PET/CT) changes from baseline and Week 52 at Week 104 (LTE Week 52) or flare - Change from baseline on electronic patient-reported outcome (ePRO): Patient's Global Assessment of Disease Activity (PGA), Pain Assessment, Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue and short form-36 (SF-36) at Week 76 (LTE Week 24), Week 104 (LTE Week 52) or Flare visit. Change from baseline on clinician reported outcome: Physician's Global Assessment of Disease Activity (PhGA) at Week 76 (LTE Week 24) Week 104 (LTE Week 52) or Flare visit. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Immunogenicity Biomarkers PD markers |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 27 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 5 |